Tevogen Advances Strategic CRO Evaluation to Expand Clinical Research Delivery Capabilities and Drive Revenue Growth Tevogen Advances Strategic CRO Evaluation to Expand Clinical Research Delivery Capabilities and Drive Revenue Growth Potential transaction expected to add $20M+ in revenue and support double-digit growth, further strengthening Tevogen’s position in oncology, rare diseases, and medical devicesTarget CRO operates across 20+ countries, providing global clinical development capabilities WARRE ...

Tevogen Regains Compliance with Nasdaq Minimum Bid Price Requirement Tevogen Regains Compliance with Nasdaq Minimum Bid Price Requirement WARREN, N.J., March 25, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) received written notice (the “Notification Letter”) from The Nasdaq Stock Market LLC notifying the Company that it had regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5450(a)(1) for continued listing on The Nasd ...

Group 1 - Tevogen Bio Holdings Inc. announced that Mittul Mehta, Chief Information Officer, will speak at the Microsoft Fabric Community Conference (FabCon 2026) from March 16–20, 2026, in Atlanta, Georgia [1] - Mr. Mehta will participate in sessions discussing the transformation of data engineering through agentic AI, focusing on adaptive workflows and governance considerations [1][2] - Tevogen.AI aims to apply advanced machine learning to biomedical discovery, including a published international patent application for predicting immunologically active peptides [2] Group 2 - Tevogen is a healthcare enterprise focused on affordability, efficiency, and scientific rigor, leveraging AI and precision T cell therapy to develop life-saving therapies [4] - The company has completed a proof-of-concept clinical trial for its genetically unmodified allogeneic T cells, with a pipeline that includes virology, oncology, and neurology [5] - Tevogen.AI is designed to enhance drug development by accelerating target detection and optimizing clinical trial design through predictive technologies [6] Group 3 - Tevogen is exploring strategic initiatives in domestic generics, biosimilars, medical devices, and innovative insurance solutions to broaden patient access and advance sustainable innovation [7] - The company collaborates with technology leaders like Microsoft and Databricks to support its long-term goals in therapeutic discovery [6]

Core Insights - Tevogen Bio Holdings Inc. is reaffirming its commitment to capital discipline and strategic growth, with a focus on maintaining shareholder value and operational efficiency [13][14]. Capital Management - The company does not anticipate utilizing more than 1% of its total authorized shares over the next twelve months or until it becomes cash-flow positive [2][14]. - Approximately one-fifth of total shares outstanding are in the tradable float, considering the holdings of the lead investor, directors, and named executive officers [2][14]. Shareholder Engagement - The lead investor, Dr. Manmohan Patel, expresses strong confidence in Tevogen's proprietary ExacTcell™ platform and intends to maintain his current shareholdings [2][14]. - The Board of Directors is evaluating the potential declaration of a one-time special cash dividend to shareholders, contingent upon achieving specified financial milestones [4][14]. Growth Strategy - Tevogen is actively evaluating acquisitions that could complement its immunotherapy and artificial intelligence platforms, with the potential to generate over $50 million in combined annual revenue [5][14]. - The company prioritizes a long-term stock-based incentive program aligned with company milestones, focusing on revenue and clinical targets [3][14]. Asset Valuation - Tevogen's intellectual property, proprietary platforms, and strategic partnerships are central to long-term value creation, with independent valuations in 2022 estimating the company at over $4 billion prior to going public [6][14]. - The company is exploring ways to better reflect the value of its assets [6][14]. Product Development - Tevogen Bio has completed a proof-of-concept clinical trial demonstrating the potential of its single-HLA-restricted, genetically unmodified allogeneic T cells, with a pipeline spanning virology, oncology, and neurology [8][14]. - Tevogen.AI aims to transform drug development by accelerating target detection and optimizing clinical trial design through proprietary predictive technologies [9][14]. Future Initiatives - The company is exploring future strategic initiatives that may include domestic generics, biosimilars, medical devices, and innovative insurance solutions for healthcare providers [10][14].

Core Insights - Tevogen is advancing the development of TVGN 489, a precision T-cell therapy aimed at addressing Long COVID, coinciding with International Long COVID Awareness Month [1][4] Group 1: Company Developments - Following a new leadership appointment on March 9, 2026, Tevogen is accelerating its "Biotech" and "Digital Health" verticals to progress TVGN 489 into the next clinical phase [2] - The company is evaluating the acquisition of Sciometrix and its Clinicus platform to enhance real-world monitoring for Long COVID patients [2][8] Group 2: Clinical Progress - Tevogen is prioritizing the development of TVGN 489, which targets the estimated 7% of U.S. adults suffering from Long COVID [3] - The proof-of-concept data indicates that none of the patients treated with TVGN 489 for acute infection developed Long COVID [4][6] Group 3: Market Reach and Infrastructure - The expanded HLA coverage of TVGN 489 now reaches 65% of the U.S. population, enhancing its potential patient eligibility [4][12] - The company is finalizing the infrastructure necessary for the next clinical phase based on the proof-of-concept data [12] Group 4: Technological Integration - Tevogen.AI aims to transform drug development by accelerating target detection and optimizing clinical trial design through predictive technologies [7] - The platform utilizes cloud and data services from major technology providers to support therapeutic discovery [7]

Core Viewpoint - Tevogen Bio Holdings Inc. is implementing a diversified growth strategy by appointing interim leaders and evaluating strategic opportunities that could generate over $50 million in annual revenues [1][2] Group 1: Leadership and Strategy - The company has appointed interim leaders across its core business verticals to execute the first phase of its growth strategy [1] - Tevogen is expected to close strategic transactions by the second quarter of 2026, pending due diligence and agreements [2] Group 2: Business Model and Innovations - Tevogen operates as a socially integrated healthcare enterprise focused on affordability, efficiency, and scientific rigor, utilizing AI and precision T cell therapy [2] - The company’s lead initiative, Tevogen Bio, has completed a proof-of-concept clinical trial for its genetically unmodified allogeneic T cells, with a pipeline that includes virology, oncology, and neurology [3] - Tevogen.AI aims to enhance drug development by improving target detection and clinical trial design through predictive technologies [4] Group 3: Future Initiatives - The company is exploring future strategic initiatives that may encompass domestic generics, biosimilars, medical devices, and innovative insurance solutions [5]

Core Viewpoint - Tevogen is focused on evolving into a sustainable, revenue-generating healthcare enterprise through strategic initiatives, including potential acquisitions to enhance its immunotherapy and artificial intelligence platforms [1][2]. Group 1: Strategic Initiatives - The company is actively evaluating potential acquisitions that are expected to operate as subsidiaries, generating positive cash flow and returns on invested capital over time [2][3]. - Preliminary evaluations suggest that the combined entities under consideration may generate aggregate annual revenues exceeding $50 million, aligning with the company's disciplined growth strategy [3]. Group 2: Commitment to Innovation - Tevogen emphasizes that innovation and affordability can coexist, maintaining a commitment to disciplined capital allocation, operational efficiency, and long-term shareholder value creation [4]. - The company aims to develop accessible immunotherapies while strengthening its financial foundation through strategic initiatives [4]. Group 3: Company Overview - Tevogen is a healthcare enterprise built on principles of affordability, efficiency, and scientific rigor, leveraging artificial intelligence and precision T cell therapy platforms [5]. - The company's lead initiative, Tevogen Bio, has completed a proof-of-concept clinical trial demonstrating the potential of its proprietary ExacTcell™ platform across various therapeutic areas [6]. Group 4: Future Directions - Tevogen is exploring future strategic initiatives that may include domestic generics, biosimilars, medical devices, and innovative insurance solutions, reflecting its mission to advance sustainable innovation and broaden patient access [8].

Core Insights - Tevogen Bio Holdings Inc. has signed a non-exclusive, non-binding Letter of Intent to evaluate a potential transaction with Apozeal Pharmaceutical Inc., which focuses on developing and manufacturing cost-effective medicines [1][2] Group 1: Proposed Transaction - The potential acquisition of Apozeal is seen as a strategic move to advance Tevogen Generics, aimed at supporting domestic pharmaceutical manufacturing and enhancing affordability and supply chain resilience in the U.S. [2] - Apozeal offers FDA-approved Abbreviated New Drug Application (ANDA) assets and a growing development pipeline, which could provide a foundation for Tevogen's generics business [2][9] - The transaction is subject to due diligence, negotiation, execution of definitive documentation, required approvals, and customary closing conditions [2] Group 2: Company Overview - Tevogen is a healthcare enterprise focused on affordability, efficiency, and scientific rigor, leveraging AI and precision T cell therapy platforms [4] - The company has completed a proof-of-concept clinical trial for its genetically unmodified allogeneic T cells, with a pipeline that includes programs in virology, oncology, and neurology [5] - Tevogen.AI aims to transform drug development by accelerating target detection and optimizing clinical trial design through predictive technologies [6] Group 3: Future Initiatives - Tevogen is exploring additional strategic initiatives, including domestic generics, biosimilars, medical devices, and innovative insurance solutions, to broaden patient access and advance sustainable innovation [7]

Core Viewpoint - Tevogen Bio Holdings Inc. has announced a reverse stock split at a ratio of 50 for 1 to comply with Nasdaq's minimum bid price requirement of $1.00, effective March 6, 2026 [1][2]. Group 1: Reverse Stock Split Details - The reverse stock split will convert every 50 shares of common stock into one share, with no fractional shares issued; instead, cash will be provided for any fractional shares [3]. - The reverse stock split will not affect stockholders' percentage of ownership, except for changes due to fractional shares, and will not impact the company's business operations or total stockholders' equity [4]. Group 2: Company Overview - Tevogen is a healthcare enterprise focused on affordability, efficiency, and scientific rigor, utilizing AI and precision T cell therapy platforms [8]. - The company has completed a proof-of-concept clinical trial for its genetically unmodified allogeneic T cells, with a pipeline that includes programs in virology, oncology, and neurology [9]. - Tevogen.AI aims to enhance drug development by improving target detection and clinical trial design through predictive technologies [10]. - Future strategic initiatives may include domestic generics, biosimilars, medical devices, and innovative insurance solutions [11].

Core Insights - Tevogen Bio Holdings Inc. has signed a non-exclusive, non-binding Letter of Intent to evaluate a potential transaction with a global Contract Research Organization (CRO), which could enhance its clinical development capabilities and transition the company into a revenue-generating healthcare enterprise [1][2] Company Overview - Tevogen is a healthcare enterprise focused on affordability, efficiency, and scientific rigor, utilizing artificial intelligence and precision T cell therapy platforms to develop advanced therapies across various therapeutic areas [4] - The company’s lead initiative, Tevogen Bio, has completed a proof-of-concept clinical trial demonstrating the potential of its genetically unmodified allogeneic T cells, with a pipeline that includes virology, oncology, and neurology [5] Strategic Initiatives - Tevogen is exploring additional transactions related to life sciences, including domestic generics, biosimilars, medical devices, and innovative insurance solutions, reflecting its mission to advance sustainable innovation and improve patient access [3][7] Technology and Innovation - Tevogen.AI aims to transform drug development by accelerating target detection and optimizing clinical trial design through proprietary predictive technologies, leveraging cloud and data services from major technology providers [6]